4 unchanged sentences
Equity Compensation Plans
−Removed: On May 23, 2021 (the “Effective Date”), our Board of Directors (the “Board”) adopted the Centry Pharma, Inc.
−Removed: Global Equity Incentive Plan (the “2021 Plan”), which will continue in effect for ten years from the Effective Date.
+Added: On May 23, 2021 (the “Effective Date”), our Board of Directors (the “Board”) adopted the Global Equity Incentive Plan (the “2021 Plan”), which will continue in effect for ten years from the Effective Date.
We intend to file one or more registration statements on Form S-8 under the Securities Act to register our shares issued or reserved for issuance under our equity incentive plans.
28 unchanged sentences
In this offering, we also issued to the investors who participated in the offering preferred investment options to purchase up to an aggregate of 1,924,689 shares of common stock, at an exercise price of $9.65 per share with a term of three and one-half years from the date of issuance.
+Added: On March 17, 2023, we filed a shelf registration statement on Form S-3 (the “Registration Statement”).
+Added: Pursuant to the Registration Statement, we may offer and sell securities having an aggregate public offering price of up to $150.0 million.
+Added: In connection with the filing of the Registration Statement, we also entered into a sales agreement with H.
+Added: Wainwright & Co.
+Added: (the “Sales Agent”), pursuant to which we may issue and sell shares of our common stock for an aggregate offering price of up to $40.0 million under an at-the-market offering program (the “ATM”), which is included in the $150.0 million of securities that may be offered pursuant to the Registration Statement.
+Added: Pursuant to the ATM, we will pay the Sales Agent a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of our common stock.
+Added: We are not obligated to make any sales of shares of our common stock under the ATM.
+Added: As of December 31, 2023, we have sold 371,743 shares of our common stock and received $5.1 million in net proceeds under the ATM.
We intend to use the net proceeds from these offerings to fund the preclinical and clinical development of NXP800 and NXP900, to continue development and sponsored research related to our current product candidates or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.